CA-ALTIUM-LLC
11.1.2024 16:01:31 CET | Business Wire | Press release
Altium, LLC (ASX: ALU), a global leader in electronics design systems, announces the launch of the BOM Portal within the Altium 365 platform. The BOM Portal is engineered to dramatically enhance collaboration between engineering and procurement teams, offering a unified approach to managing Bills of Materials (BOMs) in electronics design.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240111832527/en/
Altium 365 BOM Portal: Designed to improve collaboration between engineering and procurement (Graphic: Business Wire)
Procurement professionals now have visibility into upcoming designs before they are released, enabling them to catch issues early in the development process. Both procurement and engineering teams benefit from a comprehensive dashboard that monitors all Bills of Materials (BOMs) in production and provides immediate insights into any parts supply issues.
The BOM Portal on Altium 365 fosters efficient collaboration and informed decision-making across the product lifecycle. By integrating with top data sources like Octopart, SiliconExpert, and S&P Global, it provides companies with real-time, accurate component data. This is crucial for making smart, data-driven decisions.
"We are thrilled to unveil the BOM Portal as an integral part of our Altium 365 platform," states Ananth Avva, GM and Sr. Vice President of Cloud Platform at Altium. "With the complexities of modern electronics development in mind, the BOM Portal addresses the critical point when the process moves from design to realization. Specifically, the BOM Portal creates a digital BOM that intelligently enables procurement, manufacturing, and engineering professionals to collaborate effectively. Our unwavering commitment to revolutionizing the electronics design process is evident in this launch, aiming to enhance efficiency, mitigate risks, and ensure a cohesive workflow. This commitment is extended into the ecosystem that we are building with strategic partners such as Silicon Expert, IHS, and Z2Data."
Key Capabilities of the BOM Portal:
- BOM Management Integrated with Hardware Development: BOM Portal breaks down barriers between engineering and procurement teams, fostering direct communication and significantly reducing the risk of miscommunication, mistakes, and delays.
- Advanced Data Integration: BOM Portal provides access to real-time, detailed component information from Octopart, S&P Global (formerly IHS Markit), SiliconExpert, and soon Z2Data, enhancing the procurement and design process.
- Comprehensive BOM Management: BOM Portal equips users with tools for efficient BOM management, including automatic data enrichment with part details and lifecycle information.
- Risk Mitigation: BOM Portal proactively identifies potential supply chain disruptions and component obsolescence, enabling timely responses to component and market fluctuations.
- Cost and Time Efficiency: Up to 80% of PCB designs require part replacements, often taking 40 hours to resolve sourcing issues*. The capabilities of BOM Portal coupled with our data integrations reduces this to a fraction of the time, expediting the design process and reducing time to market.
The BOM Portal exemplifies Altium's ongoing innovation within the Altium 365 platform. It highlights Altium's dedication to creating integrated solutions for electronics development that not only reduce time to market but also enhance product quality and sustainability.
For more information, please visit https://www.altium.com/altium-365/supply-chain/bom-portal.
About Altium
Altium, LLC (ASX: ALU)
Based in San Diego, California, Altium, LLC (ASX: ALU) is a recognized leader in the global electronics sector, relentlessly pushing the boundaries of innovation with its advanced software-based solutions. For over three decades, AltiumDesigner has been the go-to PCB design tool tailored for designers and electrical engineers. Our Altium 365 platform is an open, cloud-based solution that supports every phase of the electronics development lifecycle, from the initial concept to the final product realization and guarantees a smooth, integrated, and efficient workflow throughout the product development process. Furthermore, our Octopart search engine stands as the world’s most comprehensive and trustworthy resource for locating electronic components, streamlining the sourcing process for professionals. Catering to a broad spectrum of clients, ranging from individual innovators to sprawling multinational corporations, Altium is deeply committed to arming our users and customers with the essential solutions required to turn their innovative electronic ideas into market-leading products.
*A commissioned study conducted by Forrester Consulting on behalf of Altium 365 in 2023. Results are based on a composite organization. Learn More.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111832527/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom